AVEREL: A randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for her2-positive locally recurrent/metastatic breast cancer

Journal of Clinical Oncology

Volumn 31, Issue 14, 2013, Pages 1719-1725

  Gianni, Luca ^a   Romieu, Gilles H ^e   Lichinitser, Michail ^h   Serrano, Sergio V ^k   Mansutti, Mauro ^d   Pivot, Xavier ^f   Mariani, Paola ^b,c   Andre, Fabrice ^g   Chan, Arlene ^l   Lipatov, Oleg ⁱ   Chan, Stephen ^m   Wardley, Andrew ⁿ   Greil, Richard ^o   Moore, Nicola ^p   Prot, Sylvie ^p   Pallaud, Celine ^p   Semiglazov, Vladimir ^j  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Fondazione Istituto di Ricovero e Cura A Carattere Scientifico   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

^e CENTRE VAL D AURELLE   (France)

^f UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

ⁱ Republican Clinical Oncology Dispensary   (Russian Federation)

^j N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^k BARRETOS CANCER HOSPITAL   (Brazil)

^l Mount Hospital   (Australia)

^m NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁿ CHRISTIE HOSPITAL   (United Kingdom)

^o PARACELSUS MEDICAL UNIVERSITY   (Austria)

^p F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; DOCETAXEL; HORMONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TAXOID; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ASTHENIA; CANCER RECURRENCE; CARDIOPULMONARY INSUFFICIENCY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE INTERVAL; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLOW UP; HAZARD RATIO; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HYPERTENSION; HYPERTENSIVE CRISIS; LOADING DRUG DOSE; LUNG EDEMA; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SENSORY NEUROPATHY; SEPSIS; SKIN ABSCESS; SKIN DISEASE; STOMACH HEMORRHAGE; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VISCERAL METASTASIS; WOUND HEALING IMPAIRMENT; ARTICLE; BLOOD; BREAST TUMOR; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; INFLAMMATORY BREAST CANCER; LUNG CARCINOMA; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; QUESTIONNAIRE; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPENIA; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MLCS; MLOWN;

EID: 84879477431     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.7912     Document Type: Conference Paper

References (19)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
2. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
3. Yen L, You XL, Al Moustafa AE, et al: Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19:3460-3469, 2000
4. Loureiro RM, Maharaj AS, Dankort D, et al: ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. Biochem Biophys Res Commun 326:455-465, 2005
5. Klos KS, Wyszomierski SL, Sun M, et al: ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 66:2028-2037, 2006
6. Konecny GE, Meng YG, Untch M, et al: Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10:1706-1716, 2004
7. Yang W, Klos K, Yang Y, et al: ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 94:2855-2861, 2002
8. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
9. Gray R, Bhattacharya S, Bowden C, et al: Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27:4966-4972, 2009
10. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010
11. Robert NJ, Dié ras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
12. Pegram MD, Yeon C, Ku NC, et al: Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER-2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 88:S124, 2004 (suppl 1; abstr 3039)
13. Hurvitz SA, Pegram MD, Lin L-S, et al: Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-Amplified advanced breast cancer. Cancer Res 69: 854s, 2009 (suppl; abstr 6094)
14. Martín M, Makhson A, Gligorov J, et al: Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist 17:469-475, 2012
15. Baselga J, Corté s J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
16. Hurvitz S, Dirix L, Kocsis J, et al: Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H-T) in previously-untreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011 (abstr 5001)
17. Miles DW, de Haas SL, Dirix L, et al: Plasma biomarker analyses in the AVADO phase III randomized study of first-line bevacizumab β docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer. Cancer Res 70:235s, 2010 (suppl 2; abstr P2-16-04)
18. Van Cutsem E, Jayson G, Dive C, et al: Analysis of blood plasma factors in the AVITA phase III randomized study of bevacizumab (bev) with gemcitabine-erlotinib (GE) in patients (pts) with metastatic pancreatic cancer (mPC). Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011 (abstr 803)
19. Van Cutsem E, de Haas S, Kang YK, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30:2119-2127, 2012